866-897-8297

Call Is Confidential & Toll Free

Uloric

Uloric is a xanathine oxidase (XO) inhibitor indicated in patients with gout suffering from hyperuricemia and is used in its chronic management. Uloric is not recommended for the treatment of asymptomatic hyperuricemia. Uloric is marketed under the trade name Uloric by Takeda Pharmaceuticals America, Inc., and was approved by the FDA in February 2009.

Uloric (ULORIC) is a novel, xanthine oxidase/dehydrogenase (XO/XDH) inhibitor being developed by Teijin, TAP Pharmaceuticals, and Ipsen for the treatment of gout. The currently available XO inhibitor, allopurinol, has been associated with serious instances of severe hypersensitivity, in some cases leading to fatalities. There is some suggestion that uloric is less prone to excacerbate systemic inflammatory events in animal studies.

The FDA adverse event reporting system database, AERS, indicated potential signals of uloric-associated cardiovascular thromboembolic events. AERS is not capable of establishing the causal link and detecting the true frequency of an adverse event associated with a drug. The positive IC value found in this study merits continued surveillance and assessment of cardiovascular thromboembolic events associated with Uloric.

Imprints


Drug: Uloric
Strength: 40 Mg
Pill Imprint: TAP 40
Color: Green
Shape: Round

View Images & Details

Drug: Uloric
Strength: 80 Mg
Pill Imprint: TAP 80
Color: Green
Shape: Egg-shape

View Images & Details
Disclaimer: We strive to ensure that the content on pilladdictions.com is current and factual at the time it was written. However, because new information and discoveries are always becoming available, we are not making any representations or warranties with respect to this content. Please always rely on the guidance of your physician for information about the drugs you are taking and the impacts they may or may not have on your health.

Questions About Prescription Drug Addiction?

(888) 740-2069

Questions About Prescription Drug Addiction?